The 1st China Pharmaceutical Innovation Conference (CPIC), hosted by TONACEA, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).

Benchmarking the J.P. Morgan Healthcare Conference, CPIC aims to establish a new paradigm of "Chinese Innovation – Global Translation – Shanghai Transaction." As the "premier window" for global capital and enterprises to gain insight into China's innovation ecosystem, and as the "core hub" for Chinese pharmaceutical companies to upgrade, go global, and connect with the world, CPIC is set to become the definitive barometer for annual investment and collaboration in the global health industry. The conference will feature dozens of dedicated sessions covering numerous hot topics and future directions in health industry innovation investment and globalization.

Rooted in Shanghai, Connecting the World.

The inaugural China Pharmaceutical Innovation Conference today officially announces its lineup of guiding institutions: the Shanghai Biomedical Science and Technology Industry Promotion Center, the Shanghai Innovative Drug R&D Center, the Shanghai Global Health Innovation Institute, and the Shanghai Guoshan Production-Education Integration Innovation Center will jointly serve as guiding institutions. The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has joined as a supporting organization, helping to expand the conference's global cooperation network.

From July 22 to 24 at the National Exhibition and Convention Center (Shanghai). We invite you to embark on a new journey of internationalization.

Scan the QR code to register now!
Limited-time early bird tickets at 40% off – grab yours now!!
The overseas registration link will be available soon. Stay tuned!

Guiding Institutions

01、Shanghai Biomedical Science and Technology Industry Promotion Center

As a public institution directly under the Science and Technology Commission of Shanghai Municipality, the center was established in 1994 and has been deeply engaged in the industry for nearly 30 years.

Its core functions focus on research, project management services, technology transfer, investment promotion and enterprise services, talent training, as well as human genetic resource management services and laboratory animal management in the fields of life sciences and biomedicine, promoting high-quality industrial development.

02、Shanghai Innovative Drug R&D Center (Exeliris)

Established in 2023, Exeliris is a specialized innovation platform dedicated to high-value target discovery and the development of novel therapeutics. Closely aligned with global scientific frontiers and national strategic priorities, the Center is driven by a dual focus on foundational research and independent innovation. Its core efforts are directed toward addressing major diseases—including neuropsychiatric disorders, metabolic diseases, and oncology—while advancing cutting-edge, transformative technologies.

On one front, Exeliris actively undertakes major national R&D initiatives and leads integrated industry–academia–research collaborations. The Center has established a comprehensive, end-to-end translational ecosystem to accelerate the efficient conversion of scientific discoveries into clinical and industrial applications.

In parallel, Exeliris is deeply engaged in global collaboration, building extensive end-to-end R&D partnerships with leading international universities, research institutions, and multinational biopharmaceutical companies. At the same time, it places strong emphasis on both talent recruitment and development, fostering a multi-tiered talent pipeline to underpin long-term innovation excellence.

Looking ahead, Exeliris remains committed to advancing innovation in biopharmaceutical research. It aspires to become a globally influential R&D hub and a key driver of the continued transformation and upgrading of China's pharmaceutical industry.

03、Shanghai Global Health Innovation Institute (GHII)

Global Health Innovation Institute (GHII) is China's first new research and development translation institution dedicated to global health. The Institute's funding is jointly provided by Shanghai and the Gates Foundation. On September 22, 2025, the Institute announced its official launch.

Leveraging its unique position as a non-profit organization, it provides technical support and resources to domestic and global partners, facilitates the translation of innovative R&D achievements from Shanghai and China, and accelerates their entry into international markets, contributing to improved health and well-being in low- and middle-income countries and the advancement of global health equity.

04、Shanghai National Industry-Education Integration Innovation Center

The Shanghai National Industry-Education Integration Innovation Center is an independent non-profit legal entity initiated by Fudan University in collaboration with 16 organizations including Fosun Pharma. The center operates under the supervision of Shanghai Civil Affairs Bureau with the Shanghai Municipal Education Commission as its business supervisory authority. It adopts a director responsibility system under the leadership of the board of directors.

With the mission of deepening industry-academia-research collaboration and empowering innovative development in the biotech industry, the center focuses on the fields of biomanufacturing and biotechnology. Its operations include talent cultivation, scientific research breakthroughs, proof-of-concept validation, and technology commercialization, aiming to establish itself as a core engine for the bioeconomy in the Yangtze River Delta region and a global source of biotechnology innovation.

Supporting Organization

China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)

Founded in May 1989, CCCMHPIE is the national industrial association in China devoted to promoting international trade and investment in the healthcare sector.

CCCMHPIE has a diverse membership including the major R&D facilities, manufacturers, trading companies and investment institutions in China, ranging from pharmaceuticals, medical devices and equipment, biopharmaceuticals, traditional Chinese medicines, nutraceuticals, cosmetics to foods for special medical purposes. It is a professional trade and investment promotion organization in the Chinese healthcare sector while serving as the bridge between authorities and enterprises as well as Chinese and foreign partners.